May promising drug for colon cancer tapeworm, future research

Duke University Medical Center researchers have already an FDA approved discovered that the compounds effectively "Silence" is a cellular receptor has demonstrated that with an impact on chemotherapy.

The findings of this compound in the 3rd November issue of the journal Biochemistry published, as might be useful for patients and clinicians can benefit if there is a documented increase in chemotherapy. Researchers can also use the connection to manipulate the receiver to learn more about a common way to fill the cell when the Wnt signaling pathway that requires the receiver for normal operation and can go awry in cancer.

Researchers had a choice: the libraries of hundreds of thousands of biochemical compounds display or use in a library of over 1200 approved by the FDA or biologically active compounds.

"We decided to find the road says less expensive screening FDA-approved drugs and, fortunately, we have 26 compounds that appeared to meet our goal, but one that really worked with the Frizzled receptor, Wei Chen, Ph.D., assistant professor at the University Clinic of Internal Medicine at Duke. "The objective was to compare the Frizzled receptor 1 outer membrane into the interior of the cell, which effectively inactivates the reader receiver.

The niclosamide is effective compound currently approved for use against tapeworm infections. But some patients with colon cancer, for example, a Wnt signaling pathway hyperactive and may have the effect of "calming" of blocks receiving niclosamide receptor in the Wnt signaling pathway.

"The paper provides a rationale for clinicians to consider with niclosamide at a new purpose," said Dr. Chen. "According to our results, an oncologist at Duke is being treated in the drafting of protocols for Phase 1 (safety) clinical trials for patients with colorectal cancer for our laboratory findings to bedside. "

Chen said that he was back at work, "translational science is to be truly proud."

"I am a basic scientist working with cell receptors, we have a medicinal chemist in our laboratory and our colleagues, Dr. H. Kim Lyerly, a professor of surgery, a researcher based in genetics and immune therapies against cancer, and director of the Duke Comprehensive Cancer Center, "said Chen." This type of collaboration allows me to find different shepherds quickly from the laboratory to the clinic. "